Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of April 2026. The filing details a share repurchase executed on April 17, 2026, pursuant to a non-discretionary agreement with BNP Paribas SA, originally announced on February 17, 2026.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital allocation via share buybacks and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased (April 17, 2026): 330,000 ordinary shares.
- Price Range: Lowest 2,115.00p; Highest 2,137.00p.
- Volume-Weighted Average Price (VWAP): 2,126.15p.
- Programme Progress: Since February 17, 2026, the Company has purchased 19,856,521 ordinary shares.
- Treasury Holdings: Following this purchase, the Company holds 259,747,615 ordinary shares in treasury.
- Shares in Issue: 4,056,451,419 (excluding Treasury shares).
- Treasury Voting Rights: 6.40% of total voting rights.
Material Changes
The primary material change reported is the reduction of the Company's share count in issue and the corresponding increase in treasury shares. The filing does not provide comparative financial data against prior periods to assess changes in revenue, margins, or liquidity.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding future earnings or operational strategy. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme announced on February 17, 2026.
- Confirm the impact of the 6.40% treasury holding on earnings per share (EPS) calculations.
- Review the "Risk Factors" in the 2025 Form 20-F for context on the uncertainties mentioned in the cautionary statement.
- Check subsequent filings for updates on the buyback programme's completion status or new authorizations.